BTKi in CLL and MCL From SOHO 2023

CME

Key Updates With BTK Inhibitors in CLL and MCL From SOHO 2023

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: October 18, 2023

Expiration: October 17, 2024

Catherine C. Coombs
Catherine C. Coombs, MD, MS
Toby A Eyre
Toby A Eyre, MBChB, MD

Activity

Progress
1
Course Completed

References

  1. Ghia P, Munir T, Burger JA, et al. Ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison of 3 randomized phase 3 trials. Presented at: 2023 Society of Hematologic Oncology Annual Meeting; September 6-9, 2023. Abstract CLL-194.
  2. Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353-1363. 
  3. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Eng J Med. 2023;388:319-332. 
  4. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441-3452. 
  5. Proskuriakova E, Shrestha D, Jasaraj R, et al. Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Presented at: 2023 Society of Hematologic Oncology Annual Meeting; September 6-9, 2023. Abstract CLL-428.
  6. Wang ML, Shah NN, Jurczak W, et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma: updated results and subgroup analysis from the phase 1/2 BRUIN study with 2 years of survival follow-up. Presented at: 2023 Society of Hematologic Oncology Annual Meeting; September 6-9, 2023. Abstract MCL-155.
  7. Wang ML, Jurczak W, Luigi Zinzani Pier, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988-3997. 
  8. Wierda WG, Lewis DJ, Ghia P, et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1/2 BRUIN study. Presented at: 2022 American Society of Hematology Annual Meeting and Exposition; December 10-13, 2022. Abstract 642.
  9. Lakhotia R, Pittaluga S, Phelan J, et al. Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL). Presented at: 2023 Society of Hematologic Oncology Annual Meeting; September 6-9, 2023. Abstract MCL-349.
  10. Melani C, Lakhotia R, Pittaluga S, et al. Phase 1b/2 study of ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed/refractory B-cell lymphoma: safety, efficacy and molecular analysis. Presented at: 2020 American Society of Hematology Annual Meeting and Exposition; December 4-8, 2020. Abstract 598.